ImmunityBio/$IBRX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About ImmunityBio
ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: the United States and Europe. Key revenue is generated from the United States.
Ticker
$IBRX
Sector
Primary listing
Employees
685
Headquarters
Website
ImmunityBio Metrics
BasicAdvanced
$2.5B
-
-$0.49
-0.07
-
Price and volume
Market cap
$2.5B
Beta
-0.07
52-week high
$5.66
52-week low
$1.83
Average daily volume
9.1M
Financial strength
Current ratio
4.11
Quick ratio
3.475
Long term debt to equity
-146.577
Total debt to equity
-147.883
Interest coverage (TTM)
-2.10%
Profitability
EBITDA (TTM)
-269.066
Gross margin (TTM)
99.66%
Net profit margin (TTM)
-648.57%
Operating margin (TTM)
-504.18%
Effective tax rate (TTM)
-0.01%
Revenue per employee (TTM)
$80,000
Management effectiveness
Return on assets (TTM)
-42.14%
Return on equity (TTM)
57.95%
Valuation
Price to revenue (TTM)
36.417
Price to book
-4.17
Price to tangible book (TTM)
-4.06
Price to free cash flow (TTM)
-5.779
Free cash flow yield (TTM)
-17.30%
Free cash flow per share (TTM)
-0.45
Growth
Revenue change (TTM)
4,227.22%
Earnings per share change (TTM)
-48.57%
3-year revenue growth (CAGR)
382.14%
3-year earnings per share growth (CAGR)
-19.83%
What the Analysts think about ImmunityBio
Analyst ratings (Buy, Hold, Sell) for ImmunityBio stock.
Bulls say / Bears say
ImmunityBio generated $26.4 million in revenue for Q2 2025 versus $1.0 million in Q2 2024. This marks the first quarter of significant product revenue and shows strong initial commercial momentum for ANKTIVA.
Net loss narrowed to $92.6 million in Q2 2025 from $134.6 million in Q2 2024, indicating improved operational efficiency and better expense management year-over-year.
The company stated it has sufficient cash, cash equivalents, marketable securities, and existing facilities to fund operations for the next 12 months, lowering near-term financing risks.
FDA issued a Refuse-to-File notice for the supplemental BLA targeting papillary-only NMIBC, requiring a randomized trial against chemotherapy. This delays potential approval timelines.
ImmunityBio closed an $80 million equity financing in July 2025, issuing warrants that could dilute existing shareholders by up to roughly $96 million if exercised, increasing the risk to current share count.
ImmunityBio reported a net loss of $92.6 million in Q2 2025. Despite narrowing from the previous year, this reflects continued high cash burn, underscoring ongoing pressure on liquidity and profitability.
Data summarised monthly by Lightyear AI. Last updated on 30 Aug 2025.
ImmunityBio Financial Performance
Revenues and expenses
ImmunityBio Earnings Performance
Company profitability
ImmunityBio News
AllArticlesVideos
Initial Data Shows 100% Disease Control in 5 Out of 5 Patients With Recurrent Glioblastoma With Two Patients in Near Complete Response Treated With ImmunityBio's ANKTIVA®, NK Cell Therapy Plus Optune Gio® Device
Business Wire3 weeks ago
ImmunityBio Reports Q2 Earnings Release Reflecting 60% Increase in Revenue in Q2 2025, With Year-to-Date Sales of $43 Million and 246% Unit Growth Since J-code
Business Wire1 month ago
ImmunityBio Reports 60% Increase in Revenue in Q2 2025, with Year-to-Date Sales of $43 Million and 246% Unit Growth Since J-Code with Regulatory Updates
Business Wire2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for ImmunityBio stock?
ImmunityBio (IBRX) has a market cap of $2.5B as of September 15, 2025.
What is the P/E ratio for ImmunityBio stock?
The price to earnings (P/E) ratio for ImmunityBio (IBRX) stock is 0 as of September 15, 2025.
Does ImmunityBio stock pay dividends?
No, ImmunityBio (IBRX) stock does not pay dividends to its shareholders as of September 15, 2025.
When is the next ImmunityBio dividend payment date?
ImmunityBio (IBRX) stock does not pay dividends to its shareholders.
What is the beta indicator for ImmunityBio?
ImmunityBio (IBRX) has a beta rating of -0.07. This means that it has an inverse relation to market volatility.